Compare DG & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DG | GH |
|---|---|---|
| Founded | 1939 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Department/Specialty Retail Stores | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.5B | 22.9B |
| IPO Year | 2008 | 2018 |
| Metric | DG | GH |
|---|---|---|
| Price | $130.49 | $163.18 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 31 | 26 |
| Target Price | $142.83 | ★ $201.64 |
| AVG Volume (30 Days) | 1.4M | ★ 1.9M |
| Earning Date | 12-03-2026 | 11-05-2026 |
| Dividend Yield | ★ 1.89% | N/A |
| EPS Growth | ★ 34.05 | 6.74 |
| EPS | ★ 4.49 | N/A |
| Revenue | ★ $42,724,369,000.00 | $982,021,000.00 |
| Revenue This Year | $4.27 | $38.25 |
| Revenue Next Year | $4.05 | $35.37 |
| P/E Ratio | $27.84 | ★ N/A |
| Revenue Growth | 5.20 | ★ 32.88 |
| 52 Week Low | $95.11 | $64.00 |
| 52 Week High | $158.23 | $191.05 |
| Indicator | DG | GH |
|---|---|---|
| Relative Strength Index (RSI) | 61.91 | 42.58 |
| Support Level | $115.67 | $153.88 |
| Resistance Level | $132.00 | $173.94 |
| Average True Range (ATR) | 3.66 | 7.44 |
| MACD | 0.88 | -2.28 |
| Stochastic Oscillator | 99.15 | 14.74 |
Since its beginning in 1939, Dollar General has grown to become the largest dollar store operator in the United States, with more than 20,000 small-box discount stores across 48 states. The firm generated over $42 billion in fiscal 2025 sales. The retailer maintains a heavy concentration of stores in rural and low-income markets underserved by big-box retailers. It's 11,000 stock-keeping units, including 2,000 priced at $1 or less, span consumables (82% of sales), seasonal items (10%), home products (5%), and apparel (3%). More than 20% of sales are derived from private label.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.